Piramal Pharma Ltd. Announces $90M Investment in U.S. Expansion
MUMBAI, India — May 12, 2025 — Piramal Pharma Limited, a leading global pharmaceutical company, has announced a significant investment plan to expand its operations in the United States. In conjunction with the 2025 SelectUSA Investment Summit, the company has committed $90 million towards enhancing two of its U.S. facilities.
The expansion includes the addition of commercial-scale sterile injectables capabilities at the Lexington, KY site and the development and commercial-scale capabilities in payload-linkers for bioconjugates at the Riverview, MI facility. This investment is part of Piramal Pharma’s ongoing strategy to strengthen its presence in the U.S. market and is incremental to its prior investments totaling $570 million in the country.
Piramal Pharma operates under three business verticals: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization (CDMO); Piramal Critical Care (PCC), focusing on Complex Hospital Generics (CHG); and India Consumer Healthcare (ICH), which deals with over-the-counter (OTC) products. The company’s global footprint includes approximately 17 development and manufacturing facilities across India, the UK/Europe, and North America, with a commercial presence in over 100 countries.
In addition to the expansion plans, Piramal Pharma has recently received an Establishment Inspection Report (EIR) for its Turbhe facility from the U.S. Food and Drug Administration (USFDA), further bolstering its operational capabilities in the U.S.
As of May 8, 2025, Piramal Pharma’s stock closed at 207.77 INR on the National Stock Exchange of India, with a market capitalization of 278.84 billion INR. The company’s 52-week high was 307.9 INR, and its low was 136.1 INR. The price-to-earnings ratio stands at 725.96.
This strategic investment underscores Piramal Pharma’s commitment to expanding its manufacturing and development capabilities in the U.S., aligning with its global growth objectives.